Victory Capital Management Inc. boosted its position in Omnicell Inc. (NASDAQ:OMCL) by 77.2% during the second quarter, Holdings Channel reports. The fund owned 3,069 shares of the company’s stock after buying an additional 1,337 shares during the period. Victory Capital Management Inc.’s holdings in Omnicell were worth $105,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of OMCL. Stephens Inc. AR boosted its stake in shares of Omnicell by 20.5% in the second quarter. Stephens Inc. AR now owns 5,160 shares of the company’s stock worth $177,000 after buying an additional 878 shares during the last quarter. Diversified Trust Co purchased a new stake in shares of Omnicell during the second quarter worth about $216,000. Shelton Capital Management purchased a new stake in shares of Omnicell during the second quarter worth about $267,000. Eqis Capital Management Inc. boosted its stake in shares of Omnicell by 11.9% in the second quarter. Eqis Capital Management Inc. now owns 9,163 shares of the company’s stock worth $314,000 after buying an additional 971 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Omnicell during the second quarter worth about $322,000. Institutional investors and hedge funds own 95.26% of the company’s stock.
Omnicell Inc. (NASDAQ:OMCL) traded down 0.30% during trading on Friday, hitting $36.79. The stock had a trading volume of 165,963 shares. Omnicell Inc. has a 52 week low of $25.06 and a 52 week high of $40.50. The firm has a market cap of $1.33 billion, a PE ratio of 93.38 and a beta of 0.58. The company’s 50-day moving average is $37.88 and its 200 day moving average is $33.96.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. Omnicell had a return on equity of 10.41% and a net margin of 2.36%. The company earned $175.60 million during the quarter, compared to the consensus estimate of $170.89 million. During the same period last year, the business earned $0.28 EPS. The business’s quarterly revenue was up 55.7% on a year-over-year basis. Equities analysts expect that Omnicell Inc. will post $1.58 EPS for the current fiscal year.
OMCL has been the subject of a number of research reports. Zacks Investment Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Sidoti cut Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a report on Thursday, September 8th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $46.00 target price on shares of Omnicell in a report on Tuesday, September 13th. Finally, FBR & Co upped their price target on Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 7th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $38.13.
In other news, Chairman Randall A. Lipps sold 37,425 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $37.37, for a total transaction of $1,398,572.25. Following the completion of the sale, the chairman now directly owns 192,325 shares of the company’s stock, valued at approximately $7,187,185.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP J Christopher Drew sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $37.89, for a total value of $568,350.00. Following the sale, the vice president now directly owns 139,844 shares of the company’s stock, valued at $5,298,689.16. The disclosure for this sale can be found here. Insiders own 3.75% of the company’s stock.
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.